XNPT 7.55 Xenoport Inc $XNPT Hit a 52 week high of 7.70

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
XNPT 7.55 Xenoport Inc $XNPT Hit a 52 week high of 7.70 Closing the day 11/10/14 at 7.55 +0.26 +3.57% With a day low of 7.26 and a total volume of 1,090,832.

XNPT Recent Posts: http://investorshangout.com/XenoPort-Inc-XNPT-55935/

XNPT Xenoport Inc Recent Headline News

XenoPort to Present at the Credit Suisse Healthcare Conference
Business Wire - Thu Nov 06, 12:09PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Credit Suisse Healthcare Conference in Phoenix, Arizona. The live presentation will occur at 8:30 a.m. Pacific Time (9:30 a.m. Mountain Time) on Wednesday, November 12, 2014. A replay of the presentation will also be available.
XNPT: 7.55 (+0.26)

XenoPort Has Returned 39.6% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Nov 05, 11:04AM CST
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 39.59% as of today's recent price of $7.21.
XNPT: 7.55 (+0.26)

XenoPort's (XNPT) CEO Ron Barrett on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 9:40PM CST

XNPT: 7.55 (+0.26)

XenoPort (XNPT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST

XNPT: 7.55 (+0.26)

XenoPort beats by $0.49, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:27PM CST

XNPT: 7.55 (+0.26)

XenoPort Reports Third Quarter Financial Results
Business Wire - Tue Nov 04, 3:07PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2014. Revenues for the third quarter were $31.1 million compared to $2.5 million for the same period in 2013. Revenues for the third quarter included $25.0 million in collaboration revenue resulting from XenoPort's license agreement with Reckitt Benckiser Pharmaceuticals, Inc. Net income for the third quarter was $8.3 million compared to a net loss of $18.8 million for the same period in 2013. At September 30, 2014, XenoPort had cash, cash equivalents and short-term investments of $113.4 million.
XNPT: 7.55 (+0.26)

XNPT, AMRS, GSAT, CRDC, IOSP, OKS Expected To Be Down After Next Earnings Releases
M2 - Mon Nov 03, 3:33AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, November 4th 2014 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. Xenoport Inc (NASDAQ:XNPT), AMYRIS INC (NASDAQ:AMRS), Globalstar Inc (OTC:GSAT), Cardica Inc (NASDAQ:CRDC), INNOSPEC INC. (NASDAQ:IOSP), ONEOK PARTNERS, L.P. (NYSE:OKS) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Tuesday:
AMRS: 3.04 (+0.17), IOSP: 44.06 (+0.34), OKE: 56.19 (-1.07), CRDC: 0.91 (-0.05), OKS: 48.06 (-0.35), GSAT: 2.63 (+0.01), XNPT: 7.55 (+0.26)

XenoPort Up 32.4% Since SmarTrend Uptrend Call (XNPT)
Comtex SmarTrend(R) - Wed Oct 29, 9:38AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 32.43% as of today's recent price of $6.84.
XNPT: 7.55 (+0.26)

XenoPort reports November 4
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 10:53AM CDT

XNPT: 7.55 (+0.26)

XenoPort to Release Third Quarter Financial Results on November 4
Business Wire - Thu Oct 23, 9:00AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its third quarter financial results on November 4, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay of the call will be available for one week following the event.
XNPT: 7.55 (+0.26)

XenoPort Shares Up 22.6% Since SmarTrend's Buy Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Oct 22, 9:18AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 22.56% as of today's recent price of $6.33.
XNPT: 7.55 (+0.26)

Uptrend Call Working As XenoPort Stock Rises 20.2% (XNPT)
Comtex SmarTrend(R) - Tue Oct 14, 5:17PM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 20.23% as of today's recent price of $6.21.
XNPT: 7.55 (+0.26)

Commit To Buy XenoPort At $5, Earn 15.8% Annualized Using Options
StockOptionsChannel.com - Thu Oct 09, 10:29AM CDT
Investors eyeing a purchase of XenoPort Inc shares, but tentative about paying the going market price of $5.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
XNPT: 7.55 (+0.26)

Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
Business Wire - Fri Sep 12, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.
CYTK: 4.33 (+0.23), SNTS: (), OCRX: 5.70 (+0.09), ANAC: 30.54 (+1.94), XNPT: 7.55 (+0.26)

Xenoport/NIAAA Collaborate on Alcoholism Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:55PM CDT
Xenoport, Inc. (XNPT) entered into a clinical trial collaboration agreement with the National Institute on Alcohol Abuse and Alcoholism, for a study that will evaluate HORIZANT as a potential treatment for alcohol use disorder (AUD).
CBPO: 64.30 (-4.60), CBM: 22.96 (+0.30), AMGN: 163.09 (+2.84), XNPT: 7.55 (+0.26)

XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston
Business Wire - Wed Sep 10, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on XP23829, an investigational prodrug of monomethyl fumarate (MMF), at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829.
XNPT: 7.55 (+0.26)

XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder
Business Wire - Tue Sep 09, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT.
XNPT: 7.55 (+0.26)

DTSI, XNPT, ZUMZ, BIDU, DISCA, KBE Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 04, 9:30AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of DTS, INC. (NASDAQ TSI), Xenoport Inc (NASDAQ:XNPT), Zumiez Inc (NASDAQ:ZUMZ), Baidu Inc (NASDAQ:BIDU), Discovery Communications Inc (NASDAQ ISCA), Kbw Bank Etf (NYSE:KBE) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ZUMZ: 33.91 (-1.19), DTSI: 30.71 (+0.62), KBE: 33.52 (+0.17), BIDU: 247.58 (+11.04), DISCA: 32.26 (-0.36), XNPT: 7.55 (+0.26)

XenoPort to Present at the Morgan Stanley Global Healthcare Conference
Business Wire - Tue Sep 02, 10:00AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference. The live presentation will occur at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time) on Tuesday, September 9, 2014. A replay of the presentation will also be available.
XNPT: 7.55 (+0.26), MS: 35.88 (+0.22)

XenoPort Reports Second Quarter Financial Results
Business Wire - Wed Aug 06, 3:05PM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the second quarter and six months ended June 30, 2014. Total revenues for the second quarter were $5.3 million, compared to $2.1 million for the same period in 2013. Net loss for the second quarter was $19.4 million, compared to a net loss of $24.4 million for the same period in 2013. At June 30, 2014, XenoPort had cash, cash equivalents and short-term investments of $124.9 million.
XNPT: 7.55 (+0.26)

XenoPort Inc (XNPT) Stock Research Links

XNPT Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Palmer Holland Takes Natural Colors Across North America

Updated Category News Views 27

Natural food color sounds like a tidy little ingredient story until somebody tries to keep a blue beverage blue on a retail shelf. That is where Palmer Holland's new exclusive North American commercial arrangement with BOTANIKind gets interesting. This is not a flashy public-market transaction, and neither company has handed investors a revenue figure, volume target, or...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 47

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
M.O.L.I.F.E. Brings Community Inclusion Into Public View

Updated Category News Views 138

A food pantry can reveal more about inclusion than a polished mission statement ever will. M.O.L.I.F.E., Inc. is set to be featured in an educational segment of All Access with Andy Garcia, and the useful part of this story is not the celebrity-host packaging. It is the organization’s insistence that employment, independent living, day programming, residential support,...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 30

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 74

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 112

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 101

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading

Top 5 Most Recently Viewed Articles

Mobile Homes Market Grows to $16.62B by 2031

Updated Category News Views 24

Affordable Housing Fuels Mobile Homes Market When the traditional real estate market is out of reach, what's the average Joe supposed to do? Enter the mobile home market, which is expected to leap from $11.87 billion in 2026 to a hefty $16.62 billion by 2031. That's a compound annual growth rate (CAGR) of 6.96%—not too shabby for a sector often ignored by the mainstream...

Continue Reading
KinderCare Investors Face Legal Challenges Over IPO Misrepresentation

Updated Category News Views 213

Legal Action Against KinderCare Learning Companies A securities class action lawsuit has been initiated against KinderCare Learning Companies, Inc. (NYSE: KLC) and its executives. This lawsuit centers on allegations that the company misrepresented its activities and safety records during its Initial Public Offering (IPO) in October 2024. Investors who acquired KLC common...

Continue Reading
Intec Pharma Ltd's Stock Sees Decline: A Deeper Analysis

Updated Category News Views 204

Intec Pharma Ltd Faces a Rocky Road Intec Pharma Ltd (NASDAQ: INDP) is knee-deep in trouble, with its stock diving to a brutal 52-week low of $1.20. This stark drop of 56.12% over the past year paints a dismal picture for investors scoping out this biotech player. It’s no surprise that all eyes are on INDP as it struggles to navigate these choppy waters and rebuild its...

Continue Reading
Sol Rei Wine Shines at San Francisco Wine Competition

Updated Category News Views 190

Celebrating Excellence at the San Francisco Wine Competition In an impressive display of craftsmanship and quality, Sol Rei Wine has recently achieved remarkable accolades at the esteemed San Francisco Wine Competition. This boutique, women-owned wine brand has won both Double Gold and Gold medals for their exquisite offerings: the Sol Rei Syrah and the Sol Rei Private...

Continue Reading
Insight Molecular Diagnostics Gears Up for Exciting 2026 Launch

Updated Category News Views 260

Exciting Progress Ahead for Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is taking significant strides towards launching its innovative GraftAssureDx™ test in 2026. With anticipation building within the organization and among stakeholders, the company is preparing to submit its application for FDA approval by the year's end. This...

Continue Reading